Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 2
2004 6
2005 5
2006 7
2007 6
2008 10
2009 4
2010 11
2011 6
2012 8
2013 3
2014 6
2015 4
2016 4
2017 5
2018 8
2019 5
2020 10
2021 6
2022 7
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Characterization of Non-amyloidogenic G101S Transthyretin.
Wakita Y, Sato T, Chosa K, Suico MA, Sasaki R, Kawano S, Hashimoto N, Teranishi Y, Imai Y, Morioka H, Shuto T, Kai H. Wakita Y, et al. Among authors: shuto t. Biol Pharm Bull. 2018;41(4):628-636. doi: 10.1248/bpb.b17-01021. Biol Pharm Bull. 2018. PMID: 29607936 Free article.
Metformin ameliorates the severity of experimental Alport syndrome.
Omachi K, Kaseda S, Yokota T, Kamura M, Teramoto K, Kuwazuru J, Kojima H, Nohara H, Koyama K, Ohtsuki S, Misumi S, Takeo T, Nakagata N, Li JD, Shuto T, Suico MA, Miner JH, Kai H. Omachi K, et al. Among authors: shuto t. Sci Rep. 2021 Mar 29;11(1):7053. doi: 10.1038/s41598-021-86109-1. Sci Rep. 2021. PMID: 33782421 Free PMC article.
Novel Keap1-Nrf2 Protein-Protein Interaction Inhibitor UBE-1099 Ameliorates Progressive Phenotype in Alport Syndrome Mouse Model.
Kaseda S, Sannomiya Y, Horizono J, Kuwazuru J, Suico MA, Ogi S, Sasaki R, Sunamoto H, Fukiya H, Nishiyama H, Kamura M, Niinou S, Koyama Y, Nara F, Shuto T, Onuma K, Kai H. Kaseda S, et al. Among authors: shuto t. Kidney360. 2021 Dec 1;3(4):687-699. doi: 10.34067/KID.0004572021. eCollection 2022 Apr 28. Kidney360. 2021. PMID: 35721612 Free PMC article.
Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH.
Maeda H, Ishima Y, Saruwatari J, Mizuta Y, Minayoshi Y, Ichimizu S, Yanagisawa H, Nagasaki T, Yasuda K, Oshiro S, Taura M, McConnell MJ, Oniki K, Sonoda K, Wakayama T, Kinoshita M, Shuto T, Kai H, Tanaka M, Sasaki Y, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T. Maeda H, et al. Among authors: shuto t. J Control Release. 2022 Jan;341:457-474. doi: 10.1016/j.jconrel.2021.11.039. Epub 2021 Nov 29. J Control Release. 2022. PMID: 34856227
Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors.
Sasaki R, Suico MA, Chosa K, Teranishi Y, Sato T, Kagami A, Kotani S, Kato H, Hitora Y, Tsukamoto S, Yamashita T, Yokoyama T, Mizuguchi M, Kai H, Shuto T. Sasaki R, et al. Among authors: shuto t. J Pharmacol Sci. 2023 Jan;151(1):54-62. doi: 10.1016/j.jphs.2022.11.004. Epub 2022 Nov 29. J Pharmacol Sci. 2023. PMID: 36522123 Free article.
CyclosporinA Derivative as Therapeutic Candidate for Alport Syndrome by Inducing Mutant Type IV Collagen Secretion.
Kuwazuru J, Suico MA, Omachi K, Kojima H, Kamura M, Kaseda S, Kawahara T, Hitora Y, Kato H, Tsukamoto S, Wada M, Asano T, Kotani S, Nakajima M, Misumi S, Sannomiya Y, Horizono J, Koyama Y, Owaki A, Shuto T, Kai H. Kuwazuru J, et al. Among authors: shuto t. Kidney360. 2023 Jul 1;4(7):909-917. doi: 10.34067/KID.0000000000000134. Epub 2023 May 5. Kidney360. 2023. PMID: 37143203 Free PMC article.
117 results